After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring
Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.
This is a short extract from a report by MarketWatch. The full text stays with the publisher — follow the link to read it there.
Read at source